PMID- 33356033
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20221207
IS  - 1303-6165 (Electronic)
IS  - 1300-0144 (Print)
IS  - 1300-0144 (Linking)
VI  - 51
IP  - 2
DP  - 2020 Dec 28
TI  - Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on 
      sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes 
      mellitus?
PG  - 735-742
LID - 10.3906/sag-2008-37 [doi]
AB  - BACKGROUND/AIM: To evaluate the impact of treatment with sodium-glucose 
      co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), 
      and anxiety levels in patients with Type 2 diabetes mellitus (T2DM). MATERIALS 
      AND METHODS: Ninety-seven patients with type 2 diabetes admitted to tertiary care 
      hospital diabetes clinic were included. Fifty patients were randomized to receive 
      SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects 
      continued with their baseline treatment or were added other medications as needed 
      (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were 
      subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep 
      Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final 
      visit. RESULTS: Physical function, emotional role limitation, vitality, mental 
      health, pain, general health perception scores of SF-36 were significantly 
      improved in Group A, at the end of the follow-up period. There was no significant 
      change in terms of PSQ, BAI scores, and hypoglycaemia documented in all groups. 
      The intervention-related change in HbA1c level, body weight, and body mass index 
      were significantly higher in Group A. CONCLUSION: The QoL was improved in people 
      with diabetes who were taking SGLT2 inhibitors. This may be explained by weight 
      loss observed in participants.
CI  - This work is licensed under a Creative Commons Attribution 4.0 International 
      License.
FAU - Sahin, Serdar
AU  - Sahin S
AUID- ORCID: 0000-0002-6233-5418
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Haliloglu, Ozlem
AU  - Haliloglu O
AUID- ORCID: 0000-0001-8987-1942
AD  - Department of Internal Medicine, Taksim Training and Research Hospital, Istanbul, 
      Turkey
FAU - Polat Korkmaz, Ozge
AU  - Polat Korkmaz O
AUID- ORCID: 0000-0001-9692-6403
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Durcan, Emre
AU  - Durcan E
AUID- ORCID: 0000-0001-6803-4977
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Rekali Sahin, Humeyra
AU  - Rekali Sahin H
AUID- ORCID: 0000-0003-1673-2209
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Yumuk, Volkan Demirhan
AU  - Yumuk VD
AUID- ORCID: 0000-0001-6463-4916
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Damci, Taner
AU  - Damci T
AUID- ORCID: 0000-0002-2578-058X
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Ilkova, Hasan Mahmut
AU  - Ilkova HM
AUID- ORCID: 0000-0001-6054-2280
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
FAU - Osar Siva, Zeynep
AU  - Osar Siva Z
AUID- ORCID: 0000-0002-8119-5596
AD  - Department of Internal Medicine, Faculty of Medicine, Istanbul 
      University-Cerrahpasa, Istanbul, Turkey
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201228
PL  - Turkey
TA  - Turk J Med Sci
JT  - Turkish journal of medical sciences
JID - 9441758
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Anxiety/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Sleep Initiation and Maintenance Disorders/etiology/*prevention & control
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
PMC - PMC8203126
OTO - NOTNLM
OT  - Anxiety
OT  - sleep quality
OT  - quality of life
OT  - sodium-glucose co-transporter 2 inhibitor
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article. This research did not 
      receive any specific grant from funding agencies in the public, commercial, or 
      not-for- profit sectors.
EDAT- 2020/12/29 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/04/30
CRDT- 2020/12/28 07:46
PHST- 2020/08/06 00:00 [received]
PHST- 2020/12/26 00:00 [accepted]
PHST- 2020/12/28 07:46 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/04/30 00:00 [pmc-release]
AID - 10.3906/sag-2008-37 [doi]
PST - epublish
SO  - Turk J Med Sci. 2020 Dec 28;51(2):735-742. doi: 10.3906/sag-2008-37.